A PHASE 2, 2-STAGE, 2-COHORT STUDY OF TALAZOPARIB (BMN 673) ADMINISTERED TO GERMLINE BRCA MUTATION SUBJECTS WITH LOCALLY ADVANCED AND/OR METASTATIC BREAST CANCER
A PHASE 2, 2-STAGE, 2-COHORT STUDY OF TALAZOPARIB (BMN 673) ADMINISTERED TO GERMLINE BRCA MUTATION SUBJECTS WITH LOCALLY ADVANCED AND/OR METASTATIC BREAST CANCER
The purpose of this 2-stage, 2-cohort Phase 2 trial is to evaluate the safety and efficacy of talazoparib (also known as BMN 673) in subjects with locally advanced or metastatic breast cancer with a deleterious germline BRCA 1 or BRCA 2 mutation. Subjects will be assigned to either Cohort 1 or 2 based on prior chemotherapy for metastatic disease:
Inclusion Criteria:
Exclusion Criteria:
Los Angeles, California 90095-1772, United States
Los Angeles, California 90095-7349, United States
Redondo Beach, California 90277, United States
San Francisco, California 94115, United States
Indianapolis, Indiana 46202, United States
Annapolis, Maryland 21401, United States
Baltimore, Maryland 21231, United States
Lutherville, Maryland 21093, United States
Lille Cédex, 59020, France
Nantes BP 20215, 44202 Cedex 2, France